ERCP Stone Management Devices – StoneMasterV and VorticCatchV – Launched by Olympus

October 30, 2020

ERCP stone management devices StoneMasterV and VorticCatchV have been launched by Olympus.

ERCP stone management devices increase efficiency in bile duct stone management and retrieval for endoscopic retrograde cholangiopancreatography (ERCP).

“At the forefront of our product design and innovation is the desire to expand the capabilities of our physician customers. Both the StoneMasterV and VorticCatchV provide physicians greater opportunity to achieve better patient outcomes and increased procedural efficiency for difficult-to-reach stones,” said Kevin Mancini, Vice President for Endoscopy at Olympus America Inc. “We are proud to add StoneMasterV and VorticCatchV to our comprehensive EndoTherapy portfolio.”

ERCP is a common endoscopic procedure used to study the ducts that drain the liver and pancreas in order to identify blockages in the biliary or pancreatic ducts caused by stones, tumors or scarring.1 Therapeutic ERCP treatments include sphincterotomy, stone removal, stent placement, balloon dilation, and tissue sampling. Approximately 650,000 ERCP procedures are performed in the U.S. annually.

The StoneMasterV provides a two-in-one solution for optimized performance in endoscopic sphincterotomy and endoscopic papillary balloon dilation, prior to retrieving large stones from the bile duct. Saving time by eliminating the need for device exchange, endoscopic sphincterotomy with endoscopic papillary dilation has demonstrated a higher rate of success and fewer complications when removing stones equal to or greater than 12mm.2  This single device combines an electrosurgical knife, known as a sphincterotome, and a multi-sizing dilation balloon in one endoscopic device to help master difficult stone management.

Additional benefits of the StoneMasterV include:

  • Improved Visualization: The radiopaque and endoscopic center markers provide excellent visualization and controlled positioning within the papilla.
  • Enhanced Safety: The CleverCut coating at the proximal end of the cutting wire minimizes damage to the surrounding tissue, providing enhanced safety when cutting.
  • Procedural Efficiency: The short wire dilation balloon with the c-channel split provides the physician control of the guidewire.

VorticCatchV is the newest addition to Olympus’ comprehensive stone retrieval basket portfolio. The single-use nitinol retrieval basket is designed for use in ERCP and is ideal for stone extraction cases in which a balloon is unable to achieve extraction, due to the stone being located in a bile duct pocket, positioned in a narrow or intrahepatic duct, or when heavy sludge removal is required after lithotripsy.

Coming in an eight-wire configuration, VorticCatchV features a spiral design that grows tighter at the distal end enabling the capture of a wide range of stones.

Benefits of VorticCatchV design include:

  • Greater Flexibility: The nitinol wire material allows the basket to flex into bile duct pockets, resulting in improved stone retrieval performance and accessibility.
  • Shape Memory: Nitinol is a memory alloy, which is more kink resistant than stainless steel options, allowing the basket to hold its shape more effectively.
  • Maintains Full Diameter: The soft nature of nitinol wires enables the basket to fully open in narrow ducts – this ability to maintain a fully open diameter provides greater opportunity to capture difficult-to-reach stones from bile duct pockets.

References

1 “Endoscopic Retrograde Cholangiopancreatography (ERCP),” American Gastroenterological Association, August 10, 2020, https://gastro.org/practice-guidance/gi-patient-center/topic/endoscopic-retrograde-cholangiopancreatography-ercp/.
2 Kim JH, Yang MJ, Hwang JC, Yoo BM. Endoscopic papillary large balloon dilation for the removal of bile duct stones. World J Gasteroenterol. 2013;19(46):8580-8594. doi.10.3748/wjg.v19.i46.8580. 2. Rouquette O, Bommelaer G, Abergel A, Poincloux L. Large balloon dilation post endoscopic sphincterotomy in removal of difficult common bile duct stones: a literature review. World J Gastroenterol. 2014;20(24):7760-7766. doi.10.3748/wjg.v20.i24.7760.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version